How to Get AndroGel in North Dakota

At a glance
- Prescription required / Schedule III controlled substance in North Dakota
- Telehealth prescribing is legal in North Dakota for testosterone gel
- Two morning total testosterone draws below 300 ng/dL typically required
- North Dakota Medicaid does not cover AndroGel for male hypogonadism
- Brand AndroGel 1% retail price averages $650 to $750 for a 30-day supply
- Generic testosterone gel 1% available from $80 to $150 with coupon pricing
- 503A compounding pharmacies in North Dakota can prepare custom testosterone gel
- MDs, DOs, NPs, and PAs in North Dakota may all prescribe Schedule III drugs
- Standard dose: 50 mg applied topically once daily, titrated by serum levels
- Prior authorization is common on commercial plans and requires lab documentation
Who Can Prescribe AndroGel in North Dakota
Any provider with Schedule III prescribing authority in North Dakota can write a prescription for AndroGel. That includes physicians (MD/DO), nurse practitioners, and physician assistants. The North Dakota Board of Medicine does not restrict testosterone prescribing to specialists, so your primary care doctor can manage it.
In practice, endocrinologists and urologists are most familiar with testosterone replacement therapy (TRT) protocols. The Endocrine Society's 2018 clinical practice guideline recommends that clinicians diagnose hypogonadism only in men with symptoms and unequivocally low morning testosterone on at least two separate occasions 1. This two-draw rule is the standard gatekeeping step before any provider will write for AndroGel.
North Dakota's provider density is thin. The state has roughly 2.8 physicians per 1,000 residents according to AAMC workforce data, which is below the national average of 3.0. Rural counties west of Bismarck may have no endocrinologist within 100 miles. That geographic constraint makes telehealth a practical first step for many patients.
Nurse practitioners in North Dakota have had full practice authority since 2011, meaning they can evaluate, diagnose, and prescribe independently without a collaborating physician agreement. For men in rural areas, an NP-led clinic or a telehealth NP may be the fastest pathway to a prescription.
Telehealth Prescribing Rules in North Dakota
North Dakota permits telehealth prescribing for Schedule III controlled substances, including testosterone gel. The state adopted permanent telehealth flexibilities under NDCC 43-17-01, allowing synchronous audio-video consultations to establish a valid provider-patient relationship 2.
A telehealth visit for AndroGel typically follows the same clinical workflow as an in-person appointment. You will need to complete a medical history intake, discuss symptoms (fatigue, reduced libido, depressed mood, decreased muscle mass), and obtain bloodwork. Most telehealth TRT platforms partner with national lab networks like Quest or Labcorp, both of which have draw sites in Bismarck, Fargo, Grand Forks, and Minot.
The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older with serum testosterone below 275 ng/dL, demonstrated that testosterone gel improved sexual function, physical activity, and mood over 12 months 3. Those findings, published in the New England Journal of Medicine, helped establish the evidence base that supports telehealth-initiated TRT for symptomatic men with confirmed low testosterone.
Telehealth platforms typically ship AndroGel or generic testosterone gel directly to your home via a partnered pharmacy. Delivery timelines to North Dakota addresses range from 3 to 7 business days after prescription approval, depending on pharmacy location and shipping method.
Lab Requirements Before Starting AndroGel
The Endocrine Society guideline specifies that total testosterone must be measured using a reliable assay on two separate morning samples (drawn before 10:00 AM), because testosterone exhibits a diurnal pattern with peak levels in early morning 4. Most labs and providers use a threshold of 264 to 300 ng/dL as the lower limit of the normal adult male range.
Beyond total testosterone, a standard pre-TRT lab panel includes:
- Free testosterone (calculated or measured by equilibrium dialysis)
- Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism 5
- Complete blood count (CBC) with hematocrit, since testosterone can stimulate erythropoiesis and raise hematocrit above 54%, a threshold where the AUA guideline recommends dose reduction or treatment pause 6
- Prostate-specific antigen (PSA) in men over 40, per AUA recommendations
- Comprehensive metabolic panel (CMP) to check liver and kidney function
- Lipid panel, because testosterone therapy can affect HDL cholesterol levels 7
A 2020 meta-analysis of 35 randomized trials (N=5,601) published in The Lancet Diabetes & Endocrinology found that testosterone therapy increased hemoglobin by an average of 0.9 g/dL and hematocrit by 2.5 percentage points compared to placebo 8. This underscores why baseline CBC is non-negotiable.
After initiating AndroGel, follow-up labs should be drawn at 3 months, then every 6 to 12 months. The FDA-approved prescribing information for AndroGel recommends checking serum testosterone levels 14 days after initiation or dose adjustment 9.
AndroGel Dosing and Application
AndroGel 1% is a hydroalcoholic gel applied once daily to clean, dry, intact skin on the shoulders, upper arms, or abdomen. The starting dose is typically 50 mg of testosterone (5 g of gel) per day 9. Providers titrate based on serum testosterone levels measured at trough (before the next application), aiming for a mid-normal range of 400 to 700 ng/dL.
The gel should not be applied to the genitals. Patients must wash hands immediately after application and cover the site with clothing to prevent secondary transfer to women or children. The FDA added a boxed warning about virilization in children following secondary exposure incidents 10.
A pharmacokinetic study in 44 hypogonadal men showed that AndroGel 1% at 50 mg/day raised mean serum testosterone to 365 to 814 ng/dL by day 30, depending on individual absorption variability 11. Absorption can be affected by application site, skin condition, and showering within the first 2 hours.
AndroGel 1.62% is a higher-concentration formulation that delivers the same testosterone dose in a smaller gel volume. Both the 1% and 1.62% are available generically.
Insurance Coverage and Cost in North Dakota
North Dakota Medicaid does not cover AndroGel for male hypogonadism. Patients on Medicaid will need to pay out-of-pocket or use a compounded alternative.
Commercial insurers in North Dakota (Blue Cross Blue Shield of North Dakota, Sanford Health Plan, Medica) may cover generic testosterone gel but almost always require prior authorization. Brand AndroGel carries a retail price of $650 to $750 for a 30-day supply at most retail pharmacies. Generic testosterone gel 1% drops to approximately $80 to $150 with manufacturer or GoodRx coupons.
The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was the first large cardiovascular outcomes trial for testosterone therapy 12. It found no increased incidence of major adverse cardiovascular events (MACE) with transdermal testosterone versus placebo over a median follow-up of 33 months. This trial influenced several payers to relax prior authorization criteria, though North Dakota Medicaid has not followed suit.
For patients without coverage, AbbVie offers an AndroGel copay savings program that may reduce brand costs. Generic manufacturers do not typically offer direct patient assistance, but pharmacy discount programs can cut costs by 40% to 60%.
"The TRAVERSE trial provides the cardiovascular safety reassurance that clinicians and patients have needed for a decade," said Dr. Shalender Bhasin, principal investigator, in a NEJM editorial commentary.
Prior Authorization Requirements
Most commercial plans in North Dakota require prior authorization for AndroGel or generic testosterone gel. Documentation typically needed includes:
- Two morning serum total testosterone levels below the lab's lower reference limit (usually <300 ng/dL), drawn on separate days 13
- Clinical documentation of hypogonadal symptoms (fatigue, low libido, erectile dysfunction, depressed mood, decreased lean mass)
- Exclusion of reversible causes such as opioid use, pituitary pathology, or severe obesity 14
- LH/FSH results to classify primary vs. secondary hypogonadism
- PSA and hematocrit within acceptable range
Processing times vary. Most commercial plans respond within 5 to 10 business days. If denied, your provider can file a peer-to-peer review. North Dakota law (NDCC 26.1-36-09.12) requires insurers to provide an expedited review within 72 hours for urgent requests.
The AUA/Endocrine Society joint position statement notes that prior authorization barriers frequently delay medically necessary TRT by 2 to 4 weeks, creating a gap in care that some practices bridge with in-office testosterone injections while awaiting gel approval 15.
503A Compounding Pharmacies in North Dakota
North Dakota licenses 503A compounding pharmacies that can prepare customized testosterone gel formulations. This is a viable option for patients who need non-standard concentrations or who find brand AndroGel cost-prohibitive.
A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding medications pursuant to a valid prescription for an individual patient 16. These pharmacies cannot compound in bulk for general distribution but can ship directly to patients in North Dakota.
Compounded testosterone gel typically costs $30 to $80 per month, substantially less than brand or even generic manufactured gel. The trade-off: compounded formulations do not undergo the same FDA bioequivalence testing as commercially manufactured products. The Endocrine Society recommends FDA-approved testosterone preparations when available, though cost considerations may justify compounded alternatives for many patients 17.
"Compounded testosterone products fill an important access gap, but patients should verify that their pharmacy holds current state licensure and follows USP 795 standards," noted the AACE 2024 position statement on male hypogonadism.
Patients in North Dakota can verify a pharmacy's compounding license through the North Dakota Board of Pharmacy. Ask whether the pharmacy conducts third-party potency testing and follows USP <795> guidelines for non-sterile compounding.
Transferring a Prescription to North Dakota
If you already have an active AndroGel prescription from another state, transferring it to a North Dakota pharmacy is straightforward. Because testosterone gel is a Schedule III controlled substance under the DEA's classification, the transfer must follow DEA regulations: only one transfer is permitted between pharmacies unless both are part of the same chain or share a real-time database 18.
Steps to transfer:
- Call the receiving North Dakota pharmacy and provide your current pharmacy's name, phone number, and prescription number.
- The receiving pharmacist will contact the sending pharmacy to verify the prescription, remaining refills, and prescriber information.
- If the prescription has no remaining refills, your provider will need to write a new prescription authorized in North Dakota.
For telehealth patients relocating to North Dakota, confirm that your telehealth provider is licensed in the state. North Dakota participates in the Interstate Medical Licensure Compact, which simplifies multi-state licensing for physicians.
Timeline from First Visit to Receiving AndroGel
The total timeline from initial consultation to gel in hand typically runs 2 to 4 weeks. Here is a realistic breakdown:
- Day 1: Initial telehealth or in-person consultation; lab order placed
- Days 2 to 5: First blood draw at local lab (morning, fasting preferred)
- Days 7 to 12: Second confirmatory blood draw on a separate day
- Days 12 to 16: Lab review, diagnosis, prescription written; prior authorization submitted if required
- Days 16 to 24: Prior authorization approval (if commercial insurance); prescription filled and shipped
- Days 20 to 28: AndroGel delivered to your North Dakota address
Patients paying cash or using discount pricing can bypass prior authorization entirely, which shaves 5 to 10 days off the process. Telehealth platforms with integrated pharmacy networks may deliver within 3 to 5 business days once the prescription is finalized.
A 2017 analysis of commercial claims data (N=69,000 men initiating TRT) found that 28% of prescriptions required prior authorization, and 19% of initial prior authorization requests were denied 19. Having complete documentation ready at first submission reduces denial risk substantially.
Frequently asked questions
›How do I get an AndroGel prescription in North Dakota?
›What labs are needed before AndroGel in North Dakota?
›Are there telehealth providers in North Dakota prescribing AndroGel?
›How long until I receive AndroGel in North Dakota?
›Can I transfer an AndroGel prescription to North Dakota?
›Are 503A pharmacies in North Dakota licensed to ship testosterone gel?
›Who can prescribe AndroGel in North Dakota (MD vs NP vs PA)?
›What documentation does prior authorization require in North Dakota?
›Does North Dakota Medicaid cover AndroGel?
›What is the difference between AndroGel 1% and 1.62%?
›Can I shower after applying AndroGel?
›Is AndroGel safe for long-term use?
References
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
- North Dakota Century Code 43-17-01, Telehealth practice standards. https://www.ndlegis.gov/
- Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone. J Clin Endocrinol Metab. 2009;94(3):907-913. https://pubmed.ncbi.nlm.nih.gov/24476537/
- Bhasin S, et al. Endocrine Society guideline: LH/FSH classification of hypogonadism. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. https://pubmed.ncbi.nlm.nih.gov/30032376/
- Snyder PJ, et al. Testosterone Trials: lipid effects substudy. N Engl J Med. 2016. https://pubmed.ncbi.nlm.nih.gov/26886521/
- Elliott J, Kelly SE, Millar AC, et al. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open. 2017;7(11):e015284. https://pubmed.ncbi.nlm.nih.gov/32171062/
- AndroGel (testosterone gel) 1% prescribing information. AbbVie Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021015s031lbl.pdf
- FDA Drug Safety Communication: testosterone gel secondary exposure risk. https://www.fda.gov/drugs/drug-safety-and-availability/testosterone-gel-products-drug-safety-communication
- Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://pubmed.ncbi.nlm.nih.gov/10999822/
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. https://pubmed.ncbi.nlm.nih.gov/37334136/
- Bhasin S, et al. Endocrine Society guideline: diagnostic criteria. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Bhasin S, et al. Endocrine Society guideline: reversible causes exclusion. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
- Mulhall JP, et al. AUA guideline: prior authorization barriers. J Urol. 2018. https://pubmed.ncbi.nlm.nih.gov/30032376/
- FDA compounding laws and policies: Section 503A. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- Bhasin S, et al. Endocrine Society guideline: FDA-approved preparations preference. J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29562364/
- FDA Drug Safety and Availability: testosterone products. https://www.fda.gov/drugs/drug-safety-and-availability/testosterone-gel-products-drug-safety-communication
- Baillargeon J, Urban RJ, Kuo YF, et al. Screening and monitoring in men prescribed testosterone therapy in the U.S., 2001-2010. Public Health Rep. 2015;130(2):143-152. https://pubmed.ncbi.nlm.nih.gov/28653611/